We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) stands against other stocks that fall behind amid market optimism.
Wall Street’s main indices rebounded from hefty losses on Wednesday after President Donald Trump announced that the US will pause the imposition of higher tariffs on 75 countries for 90 days.
In a post on Truth Social, Trump said that more than 75 countries have called to negotiate and have not retaliated in any way.
“I have authorized a 90-day PAUSE, and a substantially lowered Reciprocal Tariff during this period, of 10%, also effective immediately,” he noted.
Following the announcement, the Dow Jones jumped by 7.87 percent, the S&P 500 surged by 9.52 percent, and the tech-heavy Nasdaq soared by 12.16 percent.
Despite the overall market optimism, 10 companies, predominantly in the biopharmaceutical sector, registered losses amid the lack of fresh developments to spark buying appetite.
In this article, we listed Wednesday’s 10 worst performers and detailed the reasons behind their drop.
To come up with the list, we considered only the stocks with over $1 million in trading volume.
A close-up of a biotechnology machine working on an oncology therapy.
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA)
ZyVersa Therapeutics dropped its share prices by 18.90 percent on Wednesday to finish at $1.03 apiece, following a surge in its stock price the prior day.
The latest stock price was just 3-cents shy anew of the $1 minimum bid price requirement of the Nasdaq, having surged to $1.27 on Tuesday from $0.5820 last Monday.
Tuesday’s return to the $1 level snapped 24 consecutive days of trading below the minimum bid price requirement. Under the Nasdaq rules, companies are required to stay afloat at the $1 minimum bid price in order to stay listed.
In recent news, ZVSA said it narrowed its net loss last year by 90 percent to $9.4 million from $98.3 million in 2023, on the back of the absence of impairment charges that were recorded in 2023.
The company said it continues to focus on the development of its drug candidates, VAR 200, aimed at treating renal diseases, and IC 100, for the treatment of inflammatory conditions.
Both candidates are in various stages of preclinical and clinical development.
Overall, ZVSA ranks 3rd on our list of stocks that fall behind amid market optimism. While we acknowledge the potential of ZVSA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ZVSA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.